Back to search results

Observational Study on Liver X Receptor (LXR) in Diabetic Retinopathy

This observational study is looking into how Liver X Receptors (LXR) might help with diabetic retinopathy (DR), a common eye complication of diabetes. Researchers believe that activating LXR, which helps control cholesterol, could protect the retina and improve the function of reparative cells while reducing inflammation. The study aims to understand the specific ways LXR activation works. You may be able to join if you are between 21 and 98 years old and have diabetes or are a healthy older adult. The main goal is to assess the function of CD34+ cells (a type of cell involved in repair) from a blood sample. The current status of this study is unclear.

Study design
This is an observational study with a planned enrollment of 104 participants. It is not a treatment study, but rather aims to understand biological mechanisms.
What's involved
You would provide a blood sample, from which CD34+ cells will be isolated and tested for up to 48 hours. The record does not specify any other visits or procedures.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, assessing CD34+ cell function, is measured from blood draw to 48 hours. No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03403686

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Recruiting
Not specifiedAges 21–98Observational
University of Alabama at Birmingham
~104 participants
Updated 2025-09-17 on ClinicalTrials.gov
What's tested:blood draw

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assessing CD34+ cells function
Measured over from blood draw to 48 hours

Conditions

Diabetic Retinopathy

Explore related trials

Diabetic Retinopathy

Where it's being run

1 sites across 1 states
Alabama1

Study leadership

  • Maria B Grant, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Jennifer Moorer
[email protected]
205 325 8674
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must either carry the diagnosis of diabetes or be a healthy aged control and b) the patient be willing and have the ability to cooperate with the protocol.

What this trial measures

  • Assessing CD34+ cells functionfrom blood draw to 48 hours

    We are isolating CD34+ cells from peripheral blood and then examining the cell membrane characteristics of CD34+ cells and their in vitro function.